AzTrials
AzTrials

Advanced Triple-Negative Breast CancerPhase 2NCT06685796

A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

A Phase 2 study testing BEBT-209 capsules, Carboplatin injection and Gemcitabine hydrochloride for injection in people with Advanced Triple-Negative Breast Cancer, run by BeBetter Med Inc at 2 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast cancer (TNBC). Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Advanced Triple-Negative Breast Cancer
What is being tested?
BEBT-209 capsules, Carboplatin injection and Gemcitabine hydrochloride for injection
Could I receive a placebo?
No, everyone receives an active treatment
How many people
65 participants
Where
2 sitesChina
Study dates
12 Apr 2023to 29 May 2026
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age: ≥18 years old, female;
  • The subject has fully understood and is willing to sign the Informed Consent Form (ICF);
  • Confirmed diagnosis of HR-negative, HER2-negative locally recurrent or metastatic breast cancer by pathological biopsy;
  • Estrogen and progesterone receptor immunohistochemical assessment of tumor tissue is negative (defined as <1% nuclear staining), and HER2 is negative (i.e., no overexpression, including local immunohistochemical assessment [0 or 1+], or immunohistochemical assessment [2+] with negative in situ hybridization testing);
  • The subject has previously received 1-2 lines of systemic treatment (if progression within 12 months after the last treatment of adjuvant/new adjuvant, it can be considered as one line of treatment);
  • At least one measurable lesion in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria;
Show all 17Show fewer
  • Eastern Cooperative Oncology Group (ECOG) score of 0-1 , and no decline in physical performance in the past two weeks;
  • Life expectancy of at least 12 weeks;
  • Adequate organ and bone marrow function, defined as follows:
  • Absolute neutrophil count (ANC) ≥ 1500/mm³ (1.5 × 10^9/L);
  • Platelets ≥ 100,000/mm³ (100 × 10^9/L);
  • Hemoglobin ≥ 9 g/dL (90 g/L);
  • Alanine Aminotransferase (ALT) or Aspartate Transaminase (AST) both ≤ 2.5 × ULN, when liver metastasis is present, ALT or AST both ≤ 5.0 × Upper limit of normal value (ULN);
  • Total bilirubin (TBIL) ≤ 1.5 × ULN, when liver metastasis is present, ≤ 3.0 × ULN;
  • Serum creatinine ≤ 1.5 × ULN or estimated creatinine clearance ≥ 60 mL/min (based on the Cockcroft and Gault formula);
  • All acute toxic reactions from previous anticancer treatments or surgical procedures have resolved to baseline severity or National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 ≤ Grade 1 (except for alopecia or other toxicities that the investigator deems have no safety risk to the patient);
  • Women of childbearing age must have a negative serum pregnancy test within 7 days prior to the start of study medication, and must be willing to use a medically recognized, highly effective contraceptive method (such as intrauterine device, birth control pills, or condoms) during the study period and for one month after the last administration of the study medication.

Who cannot join

  • Previous treatment with gemcitabine;
  • Previous treatment with carboplatin for locally recurrent unresectable or metastatic breast cancer is allowed if it was administered in the adjuvant or neoadjuvant setting more than 6 months before the first metastatic relapse;
  • Concurrent central nervous system metastases or leptomeningeal disease requiring immediate radiotherapy or corticosteroid treatment; patients must discontinue steroid medication for at least 14 days before the first administration of the study drug. No stereotactic radiosurgery within 7 days or whole brain radiotherapy within 14 days before the first administration of the study drug;
  • Previous receipt of hematopoietic stem cell or bone marrow transplantation;
  • Within 7 days prior to study entry, the patient has received the following treatments:
  • Medications known to be strong inhibitors/inducers of CYP3A4;
Show all 19Show fewer
  • Medications known to significantly prolong the QT interval or cause torsades de pointes (antiarrhythmic drugs such as quinidine, disopyramide, procainamide, sotalol, etc.);
  • Within 14 days prior to study entry, the patient has received radiotherapy, or within 21 days prior to study entry, the patient has received other investigational drug treatment or cytotoxic chemotherapy;
  • Known history of hypersensitivity or suspected allergic symptoms to any component of BEBT-209, carboplatin, or gemcitabine;
  • In a resting state, the average corrected QT interval (QTc) obtained from 3 Electrocardiogram (ECG) examinations is >480msec (corrected using the Fridericia method); history of long QT syndrome or confirmed family history of long QT syndrome; history of clinically significant ventricular arrhythmias, or current use of antiarrhythmic drugs or implantation of defibrillation devices for the treatment of ventricular arrhythmias;
  • Uncontrolled electrolyte disturbances that may affect the action of QTc-prolonging drugs (such as hypocalcemia <1.0mmol/L, hypokalemia < lower limit of normal, hypomagnesemia <0.5mmol/L), but re-screening is allowed after interventional treatment;
  • History of myocardial infarction, severe/unstable angina, persistent arrhythmias ≥ Grade 2 according to NCI CTCAE version 5.0, any grade of atrial fibrillation, coronary/ peripheral artery bypass surgery, symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism);
  • Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or any upper gastrointestinal surgery including gastrectomy; known malabsorption syndrome or other conditions that may impair the absorption of BEBT-209;
  • Clinically significant active infections, including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related diseases. Active hepatitis B is defined as positive for hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg), and HBV-DNA greater than the upper limit of normal for the research center. Patients with quantitative HBV DNA greater than the upper limit of normal for the research center are allowed to receive antiviral treatment before screening to reduce the viral load to within the normal range, but must continue to receive antiviral treatment for hepatitis B during the trial; active hepatitis C is defined as HCV RNA above the detection limit;
  • Diabetes with poor blood sugar control as judged by the investigator;
  • Women who plan to conceive again within 5 years without having undergone oocyte cryopreservation;
  • Recent or active suicidal ideation or behavior;
  • Currently participating in or about to participate in other interventional clinical trials;
  • Other serious acute or chronic medical or psychiatric conditions or laboratory test abnormalities that may increase the risk of participating in the study or the risk associated with the administration of the study drug, or interfere with the study results, and any other conditions that the investigator deems the patient is not suitable to participate in this study.

Trial locations and contacts

2 sites in 1 country.

China2 sites

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510120

Other trials in China

About this study

Official title: A Phase II Study of BEBT-209 in Combination With Carboplatin and Gemcitabine for the Treatment of Advanced Triple-Negative Breast Cancer

This is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast cancer (TNBC).

Read the detailed description

This study is designed with a total of 3 cohorts, enrolling patients with advanced triple-negative breast cancer. Subjects are randomly assigned to each cohort in a 1:1:1 ratio. Each cohort initially enrolls no fewer than 8 subjects for safety assessment, with the assessment period being the first cycle of medication (21 days). If the overall safety assessment is tolerable, the enrollment will be expanded to 30-40 subjects. During the trial, if the subjects in any of the above cohorts are unable to tolerate the treatment or there is no clinical benefit, the enrollment for that cohort will be terminated promptly.

Dosing Regimen Exploration Stage: A total of 3 cohorts are designed, namely Cohort 1, Cohort 2, and Cohort 3. Cohort 1 receives carboplatin and gemcitabine treatment, with medication administered on days 1 and 8 of each cycle, with a 21-day cycle; Cohort 2 receives BEBT-209 capsules + chemotherapy (carboplatin and gemcitabine), with medication administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle, where on days 1 and 8, BEBT-209 capsules 150mg are administered orally only before dinner, and on days 2 and 9, BEBT-209 capsules 150mg are administered orally before breakfast on the day of chemotherapy, along with carboplatin and gemcitabine treatment; Cohort 3 receives BEBT-209 capsules + chemotherapy (carboplatin and gemcitabine), with medication administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle, where on days 1 and 8, BEBT-209 capsules are administered orally only (150mg，twice a day, before breakfast and before dinner), and on days 2 and 9, BEBT-209 capsules 150mg are administered orally before breakfast on the day of chemotherapy, along with carboplatin and gemcitabine treatment. If the safety assessment deems the BEBT-209 dosing regimen in Cohort 2 and Cohort 3 to be intolerable, the investigators may adjust the dosing regimen design for BEBT-209 capsules.

Expansion Stage: Investigators determine the expansion cohort for a specific dosing regimen based on the combined results of safety and pharmacodynamics observed in the dosing regimen exploration stage, further exploring the safety and efficacy of BEBT-209 capsules in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast cancer.

The study process for each subject includes three periods: the screening period, the treatment period, and the post-treatment follow-up period. The screening period lasts up to 28 days. Subjects who meet the inclusion criteria and do not meet the exclusion criteria will be enrolled to receive treatment in a 21-day treatment cycle. Hematological assessments are conducted before and after each cycle of chemotherapy, and an overall safety assessment is conducted according to the protocol during the study period; after the first dose during the treatment period, the first two tumor assessments are conducted every 9 weeks, and from the third assessment onward, every 12 weeks. Participants can continue to receive the study medication until disease progression (PD), death, intolerable toxicity, or withdrawal of informed consent (whichever occurs first).

Being tested
BEBT-209 capsules, Carboplatin injection, Gemcitabine hydrochloride for injection
Keywords
BEBT-209, Safety, Efficacy, In Combination With Chemotherapy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BEBT-209 capsulesDrug

    Also called KCBI-0191

    BEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally once before dinner or twice (before breakfast and before dinner), and on days 2 and 9, take orally once before breakfast.

  • Carboplatin injectionDrug

    Also called NSC 241240

    Carboplatin injection, dosage: AUC 2 × (creatinine clearance rate + 25), frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.

  • Gemcitabine hydrochloride for injectionDrug

    Also called NSC 613327

    Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.

Study groups in NCT06685796
Study groupRoleWhat they receive
Cohort 1：Carboplatin and GemcitabineExperimentalCarboplatin injection, dosage:AUC 2 ×(creatinine clearance rate + 25), frequency and duration of administration: administered on days 1 and 8 of each cycle, with a 21-day cycle. Gemcitabine hydrochloride for injection, dosage:1000mg/m², frequency and duration of administration: administered on days 1 and 8 of each cycle, with a 21-day cycle.
Receives: Drug: Carboplatin injection; Drug: Gemcitabine hydrochloride for injection
Cohort 2：BEBT-209 Capsules plus Chemotherapy (Carboplatin and Gemcitabine)ExperimentalBEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally once before dinner, and on days 2 and 9, take orally once before breakfast. Carboplatin injection, dosage: AUC 2 × ( creatinine clearance rate + 25), frequency and duration of administration: administered on days 2 and 9 of each cycle, with a 21-day cycle. Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 2 and 9 of each cycle, with a 21-day cycle.
Receives: Drug: BEBT-209 capsules; Drug: Carboplatin injection; Drug: Gemcitabine hydrochloride for injection
Cohort 3：BEBT-209 Capsules plus Chemotherapy (Carboplatin and Gemcitabine)ExperimentalBEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally twice (before breakfast and before dinner), and on days 2 and 9, take orally once before breakfast. Carboplatin injection, dosage: AUC 2 × (creatinine clearance rate + 25), frequency and duration of administration: administered on days 2 and 9 of each cycle, with a 21-day cycle. Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 2 and 9 of each cycle, with a 21-day cycle.
Receives: Drug: BEBT-209 capsules; Drug: Carboplatin injection; Drug: Gemcitabine hydrochloride for injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. PFS

    Progression-free survival

    Measured: From date of administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  2. AE

    Adverse event

    Measured: From the first administration of the study drug to 28 days after the last administration of the study drug

Secondary outcomes (5)

  1. OS

    Overall survival

    Measured: From date of administration until date of death from any cause,assessed up to 24 months.

  2. ORR

    Objective response rate

    Measured: During the treatment period, the first two assessments are conducted every 9 weeks, and starting from the third assessment, they are conducted every 12 weeks,assessed up to 24 months.

  3. DCR

    Disease control rate

    Measured: During the treatment period, the first two assessments are conducted every 9 weeks, and starting from the third assessment, they are conducted every 12 weeks,assessed up to 24 months.

  4. TTR

    Time to response

    Measured: During the treatment period, the first two assessments are conducted every 9 weeks, and starting from the third assessment, they are conducted every 12 weeks,assessed up to 24 months.

  5. DOR

    Duration of Response

    Measured: During the treatment period, the first two assessments are conducted every 9 weeks, and starting from the third assessment, they are conducted every 12 weeks,assessed up to 24 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Nov 2024
  2. Study start12 Apr 2023
  3. Primary completion20 Apr 2026
  4. Study completion29 May 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This study is designed with a total of 3 cohorts, enrolling patients with advanced triple-negative breast cancer. Subjets are randomly assigned to each cohort in a 1:1:1 ratio. Each cohort initially enrolls no fewer than 8 subjects for safety assessment, with the assessment period being the first cycle of medication (21 days). If the overall safety assessment is tolerable, the enrollment will be expanded to 30-40 subjects. During the trial, if the subjets in any of the above cohorts are unable to tolerate the treatment or there is no clinical benefit, the enrollment for that cohort will be terminated promptly.
Masking
None (open label)
Enrolment
65 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06685796
Sponsor's protocol ID
GBMT-209B-P01
Status last verified
Aug 2026
First submitted
11 Nov 2024
Last updated
18 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing BEBT-209 capsules, Carboplatin injection and Gemcitabine hydrochloride for injection in people with Advanced Triple-Negative Breast Cancer, run by BeBetter Med Inc at 2 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

PFS (time frame: From date of administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06685796.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in